Horizon Therapeutics plc (NASDAQ: HZNP) shared results from a new analysis showing treatment with Uplinza reduced the severity of attacks in people with Neuromyelitis Optica Spectrum Disorder (NMOSD).

There was also a change in the Quantitative Myasthenia Gravis (QMG) score, with 69.2% of AChR+ patients in the Uplinza group improving by three or more points compared to 41.8% in the placebo group.

Effective immediately, UPLINZA will be available at all BioTek reMEDys locations. Founded in 2011, BioTek reMEDys, based in New Castle, DE, ...

Sales of rare disease drug Uplinza rose 14% to $91 million. Amgen said the FDA has accepted its application seeking approval of Uplinza as a treatment for myasthenia gravis, with a decision due by ...